0000899243-20-005517.txt : 20200221 0000899243-20-005517.hdr.sgml : 20200221 20200221184257 ACCESSION NUMBER: 0000899243-20-005517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200219 FILED AS OF DATE: 20200221 DATE AS OF CHANGE: 20200221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Katkin Keith CENTRAL INDEX KEY: 0001314596 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38667 FILM NUMBER: 20641567 MAIL ADDRESS: STREET 1: C/O UROVANT SCIENCES, INC. STREET 2: 5281 CALIFORNIA AVENUE, SUITE 100 CITY: IRVINE STATE: CA ZIP: 92617 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Urovant Sciences Ltd. CENTRAL INDEX KEY: 0001740547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 5281 CALIFORNIA AVENUE STREET 2: SUITE 100 CITY: IRVINE STATE: CA ZIP: 92617 BUSINESS PHONE: 949-226-6029 MAIL ADDRESS: STREET 1: 5281 CALIFORNIA AVENUE STREET 2: SUITE 100 CITY: IRVINE STATE: CA ZIP: 92617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-19 0 0001740547 Urovant Sciences Ltd. UROV 0001314596 Katkin Keith C/O UROVANT SCIENCES, INC. 5281 CALIFORNIA AVENUE, SUITE 100 IRVINE CA 92617 1 1 0 0 PEO;CEO/Urovant Sciences, Inc. Common Shares 2020-02-19 4 M 0 180000 3.86 A 379680 D Common Shares 2020-02-19 4 F 0 104788 13.08 D 274892 D Common Shares 2020-02-19 4 J 0 75212 13.08 D 199680 D Stock Option (Right to Buy) 3.86 2020-02-19 4 M 0 180000 0.00 A 2027-09-21 Common Shares 180000 701254 D Represents 53,119 shares surrendered to the Issuer in satisfaction of payment of exercise price and 51,669 shares surrendered to the Issuer in satisfaction of the payment of required withholding taxes in connection with the exercise of stock options. Represents the sale of 75,212 shares of common stock to Sumitovant Biopharma Ltd., a subsidiary of Dainippon Sumitomo Pharma, in a privately-negotiated transaction. All of the shares underlying this option are vested and exercisable as of the date hereof. Following the reported transactions, the Reporting Person beneficially owns options to purchase an aggregate of 1,416,166 common shares (inclusive of the options reported in Table II, Column 9 above). /s/ Bryan Smith, Attorney-in-Fact 2020-02-21